Business
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing fo
About this update from Mdxhealth Sa
[{"type":"image","alt":"mdxhealth","displaySize":"","headline":null,"caption":"mdxhealth","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sf2Nm0vg.EDhfYYAQ2giIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc","width":300,"height":44}},"lazy":false},{"type":"text","content":"Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer","length":153,"tagName":"p"},{"type":"text","content":"IRVINE, CA – January XX, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progression and long-term treatment outcomes.","length":647,"tagName":"p"},{"type":"text","content":"Michael K. McGarrity, Chief Executive Officer of mdxhealth, commented: “This is a transformative moment for prostate cancer precision diagnostics – no other patient cohort combines this level of rigor, long-term follow-up, and potential impact on clinical practice guidelines, payer coverage and provider adoption for patients diagnosed with localized prostate cancer.”","length":369,"tagName":"p"},{"type":"text","content":"The ProtecT Trial","length":17,"tagName":"p"},{"type":"text","content":"The UK ProtecT (Prostate Testing for Cancer and Treatment) trial is widely regarded as the world’s largest randomized clinical trial of treatment effectiveness in localized prostate cancer. Following more than 1,500 men with localized disease for over two decades, the study provides unmatched long-term clinical outcome data across AS/AM, Radical Prostatectomy (RP), and Radiotherapy (RT).","length":390,"tagName":"p"},{"type":"text","content":"Profess...